BACKGROUND: Targeted hepatitis C virus (HCV) screening is recommended. Implementation of screening in emergency department (ED) settings is challenging and controversial. Understanding HCV epidemiology in EDs could motivate and guide screening efforts. We characterized the prevalence of diagnosed and undiagnosed HCV in a Midwestern, urban ED. METHODS: This was a cross-sectional seroprevalence study using de-identified blood samples and self-reported health information obtained from consecutively approached ED patients aged 18-64 years. Subjects consented to a "study of diseases of public health importance" and were compensated for participation. The Biochain ELISA kit for Human Hepatitis C Virus was used for antibody assay. Viral RNA was isolated using the Qiagen QIAamp UltraSens Virus kit, followed by real-time reverse transcription polymerase chain reaction using a Bio-Rad CFX96 SYBR Green UltraFast program with melt-curve analysis. RESULTS: HCV antibody was detected in 128 of 924 (14%; 95% confidence interval [CI], 12%-16%) samples. Of these, 44 (34%) self-reported a history of HCV or hepatitis of unknown type and 103 (81%; 95% CI, 73%-87%) were RNA positive. Two additional patients were antibody negative but RNA positive. Fully implemented birth cohort screening for HCV antibody would have missed 36 of 128 (28%) of cases with detectable antibody and 26 of 105 (25%) of those with replicative HCV infection. CONCLUSIONS: HCV infection is highly prevalent in EDs. Emergency departments are likely to be uniquely important for HCV screening, and logistical challenges to ED screening should be overcome. Birth cohort screening would have missed many patients, suggesting the need for complementary screening strategies applied to an expanded age range.
BACKGROUND: Targeted hepatitis C virus (HCV) screening is recommended. Implementation of screening in emergency department (ED) settings is challenging and controversial. Understanding HCV epidemiology in EDs could motivate and guide screening efforts. We characterized the prevalence of diagnosed and undiagnosed HCV in a Midwestern, urban ED. METHODS: This was a cross-sectional seroprevalence study using de-identified blood samples and self-reported health information obtained from consecutively approached ED patients aged 18-64 years. Subjects consented to a "study of diseases of public health importance" and were compensated for participation. The Biochain ELISA kit for Human Hepatitis C Virus was used for antibody assay. Viral RNA was isolated using the Qiagen QIAamp UltraSens Virus kit, followed by real-time reverse transcription polymerase chain reaction using a Bio-Rad CFX96 SYBR Green UltraFast program with melt-curve analysis. RESULTS:HCV antibody was detected in 128 of 924 (14%; 95% confidence interval [CI], 12%-16%) samples. Of these, 44 (34%) self-reported a history of HCV or hepatitis of unknown type and 103 (81%; 95% CI, 73%-87%) were RNA positive. Two additional patients were antibody negative but RNA positive. Fully implemented birth cohort screening for HCV antibody would have missed 36 of 128 (28%) of cases with detectable antibody and 26 of 105 (25%) of those with replicative HCV infection. CONCLUSIONS:HCV infection is highly prevalent in EDs. Emergency departments are likely to be uniquely important for HCV screening, and logistical challenges to ED screening should be overcome. Birth cohort screening would have missed many patients, suggesting the need for complementary screening strategies applied to an expanded age range.
Authors: Douglas A E White; Erik S Anderson; Sarah K Pfeil; Tarak K Trivedi; Harrison J Alter Journal: Ann Emerg Med Date: 2015-08-04 Impact factor: 5.721
Authors: David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward Journal: Clin Infect Dis Date: 2015-03-16 Impact factor: 9.079
Authors: Phillip C Moschella; Kimberly W Hart; Andrew H Ruffner; Christopher J Lindsell; D Beth Wayne; Matthew I Sperling; Alexander T Trott; Carl J Fichtenbaum; Michael S Lyons Journal: Am J Public Health Date: 2014-07-17 Impact factor: 9.308
Authors: G D Kelen; G B Green; R H Purcell; D W Chan; B F Qaqish; K T Sivertson; T C Quinn Journal: N Engl J Med Date: 1992-05-21 Impact factor: 91.245
Authors: Elissa M Schechter-Perkins; Nancy S Miller; Jon Hall; Joshua J Hartman; David H Dorfman; Chris Andry; Benjamin P Linas Journal: Acad Emerg Med Date: 2018-07-20 Impact factor: 3.451
Authors: Eshan U Patel; Oliver Laeyendecker; Yu-Hsiang Hsieh; Richard E Rothman; Gabor D Kelen; Thomas C Quinn Journal: J Clin Virol Date: 2016-05-10 Impact factor: 3.168
Authors: Lucia V Torian; Uriel R Felsen; Qiang Xia; Fabienne Laraque; Eric J Rude; Herbert Rose; Adam Cole; Angelica Bocour; Gary J Williams; Robert F Bridgforth; Lisa A Forgione; Howard Doo; Sarah L Braunstein; Demetre C Daskalakis; Barry S Zingman Journal: Am J Public Health Date: 2018-03-22 Impact factor: 9.308
Authors: Alex D Federman; Natalie Kil; Joseph Kannry; Evie Andreopolous; Wilma Toribio; Joanne Lyons; Mark Singer; Anthony Yartel; Bryce D Smith; David B Rein; Katherine Krauskopf Journal: Med Care Date: 2017-06 Impact factor: 2.983